Lovelace Biomedical Talks About Developing Novel Therapies for Cystic Fibrosis Month
May is Cystic Fibrosis (CF) month. Lovelace has been working in respiratory research for over 70 years, and has been using gene therapy...
Phages, Viruses that Attack Bacteria, Are a Potential Therapy Against Infections, Case Report Sugges
The case report of a cystic fibrosis (CF) patient suggests that phages — viruses that naturally infect and kill bacteria — are a...
SNSP113 (Previously SYGN113)
SNSP113 is an inhaled therapy being developed by Synspira Therapeutics that aims to ease pulmonary infections, airway congestion, and...
Incidence of CF-related Diabetes Stable in Pediatric CF, Canadian Study Finds
The incidence rate of cystic fibrosis-related diabetes (CFRD) in children with cystic fibrosis (CF) has remained stable over time,...
Phage viruses tailored in Pitt lab used to treat patient with drug-resistant infection Phage viruses
A cocktail of viruses developed at the University of Pittsburgh to precisely attack life-threatening bacteria resistant to antibiotics...
Early, Rapid BMI Increase May Affect Overall Growth of CF Children, Study Suggests
Rapid weight gain early in life may have a long-term negative impact on the growth of children with cystic fibrosis (CF), a study has...
Poor Oxygen Conditions May Promote P. aeruginosa Infection Over Other Pathogen in CF, Study Suggests
Poor oxygen conditions, a common trait in the lungs of cystic fibrosis (CF) patients, may help Pseudomonas aeruginosa bacteria outcompete...
Incidence of Non-CF Bronchiectasis is Rising in Germany, Study Reports
The incidence of non-cystic fibrosis bronchiectasis is rising in Germany, which necessitates a better understanding of the economic...
Decreasing Acidity of Airway Liquid in Newborn CF Patients May Reduce Infection Risk, Study Suggests
Normalizing the acidity in the thin layer of liquid covering the airways of newborns with cystic fibrosis might make them more resistant...
FDA Approves Kalydeco for Treatment of 6- to 12-month-old Infants with Cystic Fibrosis
The U.S. Food and Drug Administration (FDA) has approved Kalydeco (ivacaftor) for the treatment of infants from six to 12 months old, who...
